LAT 010
Alternative Names: LAT-010Latest Information Update: 21 Jun 2024
At a glance
- Originator Latticon Antibody Therapeutics
- Class Antineoplastics; Cytokines; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 06 Jun 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV) (NCT06277219)
- 06 Jun 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT06277219)
- 26 Feb 2024 Preclinical trials in Solid tumours in USA (unspecified route)